<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265928</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000459747</org_study_id>
    <secondary_id>UVACC-HIC-12077</secondary_id>
    <secondary_id>UVACC-PRC-36805</secondary_id>
    <secondary_id>MILLENNIUM-X05181</secondary_id>
    <secondary_id>MILLENNIUM-LYMPHOMA2</secondary_id>
    <nct_id>NCT00265928</nct_id>
  </id_info>
  <brief_title>Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>VELCADE (Bortezomib) for Injection - Phase II Study of Bortezomib and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in&#xD;
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer&#xD;
      cells and help kill them or carry cancer-killing substances to them. Giving bortezomib&#xD;
      together with rituximab may be an effective treatment for non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab&#xD;
      works in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma,&#xD;
      including Waldenstrom's macroglobulinemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the safety and tolerability of bortezomib and rituximab in patients with relapsed&#xD;
           or refractory, B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the overall response rate (partial response, complete response unconfirmed,&#xD;
           and complete response) in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Estimate the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  Estimate the time to disease progression in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds once weekly in weeks 1-4 and rituximab IV&#xD;
      over 5-6 hours once weekly in weeks 1-5*. Treatment repeats every 5 weeks for 2 courses.&#xD;
      Patients achieving stable disease or better receive an additional 4 courses of bortezomib&#xD;
      alone.&#xD;
&#xD;
      NOTE: *Patients receive rituximab in weeks 1-3 only during course 2 of treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 18&#xD;
      months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn for poor accrual&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enzyme inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>monoclonal antibody therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) including the following&#xD;
             subtypes:&#xD;
&#xD;
               -  B-cell small lymphocytic lymphoma&#xD;
&#xD;
               -  Marginal zone lymphoma (extranodal, nodal, or splenic)&#xD;
&#xD;
               -  Grade 1-3 follicular lymphoma&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
               -  Waldenstrom's macroglobulinemia&#xD;
&#xD;
          -  Bidimensionally measurable disease by CT scan with ≥ 1 lesion measuring &gt; 1.5 cm in a&#xD;
             single dimension&#xD;
&#xD;
          -  Relapsed or refractory disease after prior antineoplastic therapy, meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  No response to prior treatment&#xD;
&#xD;
               -  Relapsed disease after prior therapy&#xD;
&#xD;
          -  Confirmed CD20-positive disease by immunohistochemistry on biopsy specimen&#xD;
&#xD;
               -  Prior transformation allowed provided there is no evidence of aggressive&#xD;
                  histology on recent biopsy&#xD;
&#xD;
          -  No chronic lymphocytic lymphoma with absolute lymphocyte count &gt; 5,000/mm³&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3 (≥ 1,000/mm³ if due to extensive bone marrow&#xD;
             involvement with NHL or splenomegaly)&#xD;
&#xD;
          -  Absolute lymphocyte count ≤ 5,000/mm³ (except mantle cell lymphoma with a leukemic&#xD;
             phase)&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (4 times ULN if liver involvement&#xD;
             with NHL)&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile male and female patients must use effective contraception during study&#xD;
&#xD;
          -  No serious nonmalignant disease&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 within past 14 days&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  No uncontrolled angina pectoris&#xD;
&#xD;
          -  No severe uncontrolled ventricular arrhythmias&#xD;
&#xD;
          -  No EKG evidence of acute ischemia or active conduction system abnormalities&#xD;
&#xD;
          -  Any EKG abnormality must be documented as not medically relevant&#xD;
&#xD;
          -  No hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins&#xD;
             or any component of rituximab (including polysorbate 80 and sodium citrate dehydrate)&#xD;
&#xD;
          -  No known infection or exposure to HIV&#xD;
&#xD;
          -  No serious psychiatric or medical illness that would preclude study participation&#xD;
&#xD;
          -  No active hepatitis B infection&#xD;
&#xD;
          -  No other primary malignancy requiring active treatment&#xD;
&#xD;
          -  More than 4 weeks since prior significant traumatic injury&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 3 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery or open biopsy&#xD;
&#xD;
               -  Other diagnostic surgery allowed&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 3 months since prior unconjugated monoclonal antibody therapy&#xD;
&#xD;
          -  At least 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g.,&#xD;
             iodine I 131 tositumomab [Bexxar] or ibritumomab tiuxetan [Zevalin])&#xD;
&#xD;
          -  More than 2 weeks since prior investigational agent&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  No concurrent systemic corticosteroid at greater than the equivalent dose of 20 mg/day&#xD;
             of prednisone, unless for treatment of allergic reactions to CT scan dye&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  No other immunosuppressive agents, unless for treatment of allergic reactions to CT&#xD;
             scan dye&#xD;
&#xD;
          -  No other concurrent antilymphoma agents&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
               -  Concurrent participation in another nontreatment study allowed if it does not&#xD;
                  interfere with participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Densmore, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center at UV Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>January 24, 2008</last_update_submitted>
  <last_update_submitted_qc>January 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2008</last_update_posted>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>Waldenstrom's macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

